Ventripoint Diagnostics to Showcase VMS+ at AEPC Annual Meeting

Toronto, Ontario — May 28, 2025 — NewsWall — Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) will participate in the 58th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC) in Hamburg, Germany, from May 28th-31st, 2025.

The AEPC, the largest global association in congenital cardiology with over 1,000 members, is a network of specialists dedicated to advancing congenital cardiology. Ventripoint will exhibit at the meeting, connecting with clinicians and expanding its global network.

Ventripoint's focus is on growing its customer base and expanding the use of VMS+ in routine clinical workflow. VMS+ versions 3.2 and 4.0 provide improved product-user fit and integration into clinical workflow, enabling a more efficient patient journey by providing accurate information about the heart's structure and function, comparable to cardiac MRI.

The company also announced the postponement of its annual shareholder meeting due to a potential postal strike.

"We value the opportunity to support AEPC," said Ventripoint President and CEO Hugh MacNaught. "VMS+ provides the ability to deliver fast, affordable and accessible volumetric assessments of cardiac function throughout a patient’s life journey with accuracy comparable to cardiac MRI.”

Contact:
Hugh MacNaught
hmacnaught@ventripoint.com
(604) 671-4201

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

Source: Ventripoint Diagnostics Ltd.